[Guidelines for prophylaxis and anti-thrombotic treatment for patients with COVID-19. Consensus of the Latin American Cooperative Group on Hemostasis and Thrombosis (CLAHT)].
Guillermo-Esposito C, Casais P, Cesarman-Maus G, Andrade-Orsi F, Martínez-Rovira R, de-Campos-Guerra JC, Rezende SM, Izaguirre-Ávila R, Altman R, Ceresetto J, Colorio C, Duboscq C, Rosa CM, Molnar S, García D, Tejarina ML, García NN, Choque Pacheco J, J. María CC, Ramos Ramos G, León Basantes G, Milena Reyna A, Cantero Guevara M, Porres Aguilar M, Meillón L, Grimaldo FA, Bacon Fonseca LA, Ávila Milord A, Aguilar R, Aparicio R, de Guggiari P, Chumpitaz G, García PP, Steffano B, Damiano S, Serrano J, Zavahra M.
Guillermo-Esposito C, et al.
Arch Cardiol Mex. 2021 Dec 20;91(Suplemento COVID):047-054. doi: 10.24875/ACM.20000291.
Arch Cardiol Mex. 2021.
PMID: 33459726
Free PMC article.
Review.
Spanish.
Coagulopathy and thrombosis associated with coronavirus disease 2019 (COVID-19) represent a major issue in the management of this disease. ...This hypercoagulable state leads to an increased risk of thrombosis, which seems to be higher among those pati …
Coagulopathy and thrombosis associated with coronavirus disease 2019 (COVID-19) represent a major issue in the manageme …